Rhumbline Advisers Sells 17,705 Shares of Bath & Body Works, Inc. $BBWI

Rhumbline Advisers cut its stake in Bath & Body Works, Inc. (NYSE:BBWI) by 3.1% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 559,448 shares of the company’s stock after selling 17,705 shares during the quarter. Rhumbline Advisers owned about 0.26% of Bath & Body Works worth $16,761,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Stonehage Fleming Financial Services Holdings Ltd bought a new position in shares of Bath & Body Works in the 2nd quarter worth approximately $33,000. SVB Wealth LLC bought a new position in shares of Bath & Body Works in the 1st quarter worth about $35,000. Geneos Wealth Management Inc. grew its holdings in Bath & Body Works by 217.7% in the first quarter. Geneos Wealth Management Inc. now owns 1,169 shares of the company’s stock worth $35,000 after purchasing an additional 801 shares during the period. Parallel Advisors LLC lifted its holdings in shares of Bath & Body Works by 63.3% during the second quarter. Parallel Advisors LLC now owns 1,241 shares of the company’s stock valued at $37,000 after purchasing an additional 481 shares during the last quarter. Finally, Parkside Financial Bank & Trust increased its position in Bath & Body Works by 24.6% during the 2nd quarter. Parkside Financial Bank & Trust now owns 1,842 shares of the company’s stock valued at $55,000 after buying an additional 364 shares in the last quarter. Hedge funds and other institutional investors own 95.14% of the company’s stock.

Insider Buying and Selling at Bath & Body Works

In other Bath & Body Works news, Director Stephen D. Steinour bought 6,700 shares of Bath & Body Works stock in a transaction on Friday, November 21st. The stock was acquired at an average cost of $14.86 per share, with a total value of $99,562.00. Following the completion of the acquisition, the director owned 48,175 shares in the company, valued at approximately $715,880.50. This represents a 16.15% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Steven E. Voskuil purchased 20,000 shares of the company’s stock in a transaction dated Friday, November 21st. The shares were acquired at an average price of $15.04 per share, for a total transaction of $300,800.00. Following the purchase, the director directly owned 33,925 shares in the company, valued at approximately $510,232. The trade was a 143.63% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders have purchased 33,513 shares of company stock valued at $500,442. 0.26% of the stock is owned by corporate insiders.

Bath & Body Works Trading Up 0.7%

Shares of BBWI opened at $17.50 on Friday. The firm has a fifty day simple moving average of $23.69 and a two-hundred day simple moving average of $27.64. The firm has a market cap of $3.58 billion, a PE ratio of 5.19, a P/E/G ratio of 0.86 and a beta of 1.53. Bath & Body Works, Inc. has a 1-year low of $14.27 and a 1-year high of $41.87.

Bath & Body Works (NYSE:BBWI) last issued its quarterly earnings data on Thursday, November 20th. The company reported $0.35 EPS for the quarter, missing the consensus estimate of $0.40 by ($0.05). Bath & Body Works had a negative return on equity of 48.43% and a net margin of 9.88%.The firm had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $1.64 billion. During the same period in the previous year, the firm earned $0.49 EPS. The business’s revenue was down 1.0% on a year-over-year basis. Bath & Body Works has set its FY 2025 guidance at 2.870- EPS. Q4 2025 guidance at 1.700- EPS. As a group, research analysts forecast that Bath & Body Works, Inc. will post 3.3 EPS for the current fiscal year.

Bath & Body Works Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 5th. Investors of record on Friday, November 21st will be issued a $0.20 dividend. The ex-dividend date of this dividend is Friday, November 21st. This represents a $0.80 dividend on an annualized basis and a dividend yield of 4.6%. Bath & Body Works’s dividend payout ratio (DPR) is presently 24.62%.

Analysts Set New Price Targets

Several brokerages recently commented on BBWI. Robert W. Baird reissued a “neutral” rating and set a $19.00 price objective (down from $33.00) on shares of Bath & Body Works in a research report on Thursday, November 20th. Morgan Stanley reissued an “equal weight” rating and set a $18.00 price target (down previously from $43.00) on shares of Bath & Body Works in a research report on Friday, November 21st. JPMorgan Chase & Co. lowered their price objective on Bath & Body Works from $26.00 to $15.00 and set a “neutral” rating on the stock in a research report on Thursday, November 20th. Wells Fargo & Company decreased their price target on Bath & Body Works from $33.00 to $25.00 and set an “overweight” rating for the company in a research note on Friday, November 21st. Finally, Zacks Research cut Bath & Body Works from a “hold” rating to a “strong sell” rating in a research report on Monday, November 24th. Six analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $25.17.

About Bath & Body Works

Bath & Body Works, Inc is a specialty retailers and home to America’s Favorite Fragrances, offering a breadth of exclusive fragrances for the body and home, including the selling collections for fine fragrance mist, body lotion and body cream, 3-wick candles, home fragrance diffusers and liquid hand soap.